GPCR antagonists as an alternative to COX-2 inhibitors: a case for the PGE2 EP1 receptor

Trends Pharmacol Sci. 2006 Sep;27(9):458-60. doi: 10.1016/ Epub 2006 Jul 25.


A recent article supports the concept that prostaglandin (PG)E(2) EP(1)-receptor antagonists reduce stroke severity and cell damage; could these agents become a substitute for cyclooxygenase (COX)-2 inhibitors? The total activity of COXs--rate-limiting enzymes of PGE(2) synthesis--increases following acute neurological insult. Drugs that offer the beneficial anti-inflammatory and neuroprotective effects of PGs but that limit the negative effects of COX-2 inhibition could provide the next generation of treatment for acute neuronal damage.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Cyclooxygenase 2 Inhibitors / therapeutic use*
  • Humans
  • Neuroprotective Agents / therapeutic use*
  • Receptors, Prostaglandin E / antagonists & inhibitors*
  • Receptors, Prostaglandin E / physiology
  • Receptors, Prostaglandin E, EP1 Subtype
  • Stroke / drug therapy


  • Cyclooxygenase 2 Inhibitors
  • Neuroprotective Agents
  • PTGER1 protein, human
  • Receptors, Prostaglandin E
  • Receptors, Prostaglandin E, EP1 Subtype